Cargando…

CD133 expression in different stages of gastric adenocarcinoma

Detalles Bibliográficos
Autores principales:	Boegl, M, Prinz, C
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676557/ https://www.ncbi.nlm.nih.gov/pubmed/19367288 http://dx.doi.org/10.1038/sj.bjc.6605001

Ejemplares similares

Reply: CD133 expression in different stages of gastric adenocarcinoma
por: Smith, L M, et al.
Publicado: (2009)

Cancer Stem Cell Markers CD44, CD133 in Primary Gastric Adenocarcinoma
por: Nosrati, Anahita, et al.
Publicado: (2014)

Preliminary Study on the Expression and the Clinical Significance of CD133 in Peripheral Blood of Patients with Gastric Adenocarcinoma
por: Wu, Ju-gang, et al.
Publicado: (2014)

Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma
por: Zhao, Po, et al.
Publicado: (2010)

Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma
por: Yu, Ji-wei, et al.
Publicado: (2010)

Bony Metastasis of Gastric Adenocarcinoma
por: Devkaran, Bhavesh, et al.
Publicado: (2009)

Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas
por: Immervoll, Heike, et al.
Publicado: (2008)

Expression of CD133 and CD24 and their different phenotypes in urinary bladder carcinoma
por: Farid, Rola M, et al.
Publicado: (2019)

Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma
por: Oliver, Jaime Antonio, et al.
Publicado: (2014)

Investigation of Relationship between Hepatitis B Virus and Gastric Adenocarcinoma
por: Ghasemi, M, et al.
Publicado: (2012)

Oxytetracycline have the therapeutic efficiency in CD133(+) HCC population through suppression CD133 expression by decreasing of protein stability of CD133
por: Song, Yeonhwa, et al.
Publicado: (2018)

Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine
por: Miltiades, P, et al.
Publicado: (2014)

Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma
por: Park, Youn Young, et al.
Publicado: (2019)

CD133 Expression in the Nucleus Is Associated with Endometrial Carcinoma Staging and Tumor Angioinvasion
por: Pietrus, Milosz, et al.
Publicado: (2021)

Expression of CD133 as a cancer stem cell marker in invasive gastric carcinoma
por: Attia, S., et al.
Publicado: (2019)

Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer
por: Hashimoto, Kousuke, et al.
Publicado: (2013)

CD133 Expression and Identification of CD133/nestin Positive Cells in Rhabdomyosarcomas and Rhabdomyosarcoma Cell Lines
por: Sana, Jiri, et al.
Publicado: (2011)

A case of multiple early gastric cancers with variant differentiation including gastric adenocarcinoma of fundic gland type
por: Taniguchi, Masaaki, et al.
Publicado: (2019)

Expression of ALDH1A1 and CD133 is associated with the prognosis and effect of different chemotherapeutic regimens in gastric cancer
por: Liu, Wan-Ting, et al.
Publicado: (2019)

Immunohistochemical Expression of CD90, CD133, and TPM1 in Relation to Gastric Cancer and H. pylori Association
por: Gamal, Noha Sayed, et al.
Publicado: (2023)

KRAS, KIT and TP53 mutations in mother’s and daughter’s gastric cardia adenocarcinomas
por: Gluszek, Stanislaw, et al.
Publicado: (2018)

CD133 antigen expression in ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2009)

Comment on ‘TAp63 suppress metastasis via miR-133b in colon cancer cells'
por: Cristobal, I, et al.
Publicado: (2014)

Notch1 directly induced CD133 expression in human diffuse type gastric cancers
por: Konishi, Hidetomo, et al.
Publicado: (2016)

Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis
por: Durko, L., et al.
Publicado: (2017)

Stage I endometrial adenocarcinoma with a vaginal nodule—the importance of differential diagnosis
por: Rodrigues, Isabel, et al.
Publicado: (2022)

CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity
por: Bueno, Clara, et al.
Publicado: (2019)

DNA Damage in CD133-Positive Cells in Barrett's Esophagus and Esophageal Adenocarcinoma
por: Thanan, Raynoo, et al.
Publicado: (2016)

Response to comment on ‘TAp63 suppress metastasis via miR-133b in colon cancer cells'
por: Lin, C W, et al.
Publicado: (2014)

Stromal CD10 expression in gastric adenocarcinoma
por: Aziz, Sara Jalal, et al.
Publicado: (2022)

Corrigendum to “Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis”
por: Durko, L., et al.
Publicado: (2017)

Carcinomatous meningitis as first sign of relapse in a patient with gastric Adenocarcinoma: A rare presentation
por: Mathur, Akash, et al.
Publicado: (2017)

Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure
por: Fritzenwanger, M, et al.
Publicado: (2009)

Expression of CD 133 in Invasive Ductal Carcinoma of Breast
por: Utnal, Preeti Ashok, et al.
Publicado: (2020)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
por: Liang, Yun, et al.
Publicado: (2021)

Radiomics: a potential biomarker for N2 malignancy in clinical stage I lung adenocarcinoma
por: Deng, Jiajun, et al.
Publicado: (2020)

A Case of Gastric Adenocarcinoma With Pernicious Anemia, Polyneuropathy, and Subacute Combined Degeneration Caused by Autoimmune Gastritis
por: Kim, Sanghyun, et al.
Publicado: (2023)

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
por: Friel, Anne M, et al.
Publicado: (2010)

Multiples aberrant phenotypes in multiple myeloma patient expressing CD56(-), CD28(+),CD19(+)
por: Leite, Luiz Arthur Calheiros, et al.
Publicado: (2012)

Prognostic impact of CD133 expression in Endometrial Cancer Patients
por: Mancebo, G., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_beeeanb44a8n8p4uti460r0t7p